Venture funding for mRNA-based vaccines has decreased due to cuts in grant funding for mRNA vaccine projects, impacting biotech companies. Despite hurdles, the success of mRNA vaccines like Pfizer's and Moderna's has sparked investor interest in expanding mRNA technology to treat various diseases.